FDA批准Enspryng用于甲状腺眼病居家皮下治疗
FDA approves Enspryng for at‑home TED treatment
FDA批准Genentech的Enspryng用于甲状腺眼病居家皮下治疗。该决策基于III期SatraGO试验,其中SatraGO-2显示有效改善眼球突出和视力问题。这是首个针对该疾病的皮下治疗选项,且与神经脱髓鞘谱系疾病的安全特征一致。
原文明确指出这是首个皮下居家治疗甲状腺眼病的选项,并基于III期SatraGO试验数据,可帮助读者快速定位该批准的临床意义。
First SC option offers new flexibility for patients
The FDA has approved Genentech’s Enspryng for adults with thyroid eye disease, making it the first at‑home subcutaneous treatment option for the condition. The therapy can be administered every four weeks during the maintenance phase by the person living with TED or a caregiver after appropriate training.
Levi Garraway said: “Today’s FDA approval of Enspryng provides an important new option for people with thyroid eye disease, who have long faced limited treatment choices.
“As the first subcutaneous treatment for this condition, Enspryng offers a positive safety and efficacy profile and the potential for at-home administration.”
César A Briceño explained: “Treating thyroid eye disease requires balancing efficacy, safety and the practical realities of long-term treatment.
“As a clinical trial investigator, I have seen firsthand the potential of targeted therapies such as Enspryng. The availability of an effective subcutaneous treatment option could provide greater flexibility for both patients and physicians while reducing the logistical burden associated with infusion-based therapies.”
The approval is based on the phase 3 SatraGO programme. While SatraGO‑1 did not meet its primary endpoint at week 24, SatraGO‑2 showed significant improvements in proptosis response and diplopia reduction in the active TED population. No new safety signals were identified, with the profile consistent with that seen in neuromyelitis optica spectrum disorder.
Christine Gustafson said: “Thyroid eye disease not only affects a person’s eyes through bulging and vision problems, but it also takes a profound emotional toll on confidence, identity, relationships and daily life.
“Until now, our community has had very limited choices. The approval of Enspryng represents a critical turning point through a convenient, targeted option.”
The decision marks the second indication for Enspryng following its approval in neuromyelitis optica spectrum disorder in 2020. The medicine is also under priority review for myelin oligodendrocyte glycoprotein antibody‑associated disease and is being studied in additional autoimmune and inflammatory conditions.
来源:PharmaTimes · pharmatimes.com